statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Behind the Scenes of Apellis Pharmaceuticals's Latest Options Trends

Latest Ratings for APLS
 DateFirmActionFromTo Mar 2022Goldman SachsMaintainsBuy Mar 2022Raymond JamesMaintainsStrong Buy Jan 2022Raymond JamesMaintainsStrong Buy
 View More Analyst Ratings for...

Expert Ratings For Apellis Pharmaceuticals

WALTHAM, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant...

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the 23rd Annual Needham Virtual...

Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Crispr Therapeutics AG (CRSP Research Report) and Apellis Pharmaceuticals...

Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Apellis Pharmaceuticals (APLS)

Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Apellis Pharmaceuticals (APLS Research Report) and Bluebird Bio...

Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Bluebird Bio (BLUE)

This is a signal that APLS's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

Apellis Pharmaceuticals (APLS, $58.73) Stochastic Oscillator left the overbought zone on March 28, 2024

This is a Bullish indicator signaling APLS's price could rise from here. Traders may explore going long the stock or buying call options...

Apellis Pharmaceuticals (APLS, $58.47) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 27, 2024

It has been about a month since the last earnings report for Apellis Pharmaceuticals, Inc. (APLS). Shares have lost about 8.7% in that time frame, underperforming the S&P 500.Will the recent negative...

Apellis Pharmaceuticals (APLS) Down 8.7% Since Last Earnings Report: Can It Rebound?

With the business potentially at an important milestone, we thought we'd take a closer look at Apellis Pharmaceuticals...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS): Is Breakeven Near?

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Volume	1.25M
52-Wk High	$94.75
52-Wk Low	$19.83

APLS Apellis Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals